유방암에서 HER2 유전자 검사를 위한 자동화 은제자리부합법 검사의 유용성: 형광제자리부합법과 면역조직화학염색과의 비교
Automated Silver-enhanced In Situ Hybridization for Evaluation of HER2 Gene Status in Breast Carcinoma: Comparison with Fluorescence In Situ Hybridization and Immunohistochemistry
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background : The human epidermal growth factor receptor 2 (HER2) is amplified in 20-25% of breast cancers. HER2 overexpression or amplification is associated with a worse clinical outcome and it can predict the benefit from anthracycline and anti-HER2 therapies. The HER2 status has usually been assessed by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) in clinical samples. A new silver-enhanced in situ hybridization (SISH) technique was recently introduced. Therefore we evaluated the usefulness of SISH for detecting HER2 amplification. Methods : Tissue microarrays (TMAs) were constructed with 144 invasive breast cancer tissue samples. We performed IHC, FISH and SISH for HER2 on the tissue sections from the TMAs and we interpreted the results according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines. The concordant rates between the two different tests were calculated. Results : HER2 was overexpressed and amplified in 16.9%, 16.9%, and 18% of the cases by IHC, FISH and SISH, respectively. The concordant rates between IHC and FISH, IHC and SISH, and FISH and SISH were 95.1%, 95.7%, and 97.8%, respectively. Conclusions : SISH can be an alternative test for evaluating HER2 amplification because the 97.8% concordance with FISH satisfies the ASCO/ CAP requirement of > 95% concordance with an alternative validated method.
Abstract
Background : The human epidermal growth factor receptor 2 (HER2) is amplified in 20-25% of breast cancers. HER2 overexpression or amplification is associated with a worse clinical outcome and it can predict the benefit from anthracycline and anti-HER2 therapies. The HER2 status has usually been assessed by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) in clinical samples. A new silver-enhanced in situ hybridization (SISH) technique was recently introduced. Therefore we evaluated the usefulness of SISH for detecting HER2 amplification. Methods : Tissue microarrays (TMAs) were constructed with 144 invasive breast cancer tissue samples. We performed IHC, FISH and SISH for HER2 on the tissue sections from the TMAs and we interpreted the results according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines. The concordant rates between the two different tests were calculated. Results : HER2 was overexpressed and amplified in 16.9%, 16.9%, and 18% of the cases by IHC, FISH and SISH, respectively. The concordant rates between IHC and FISH, IHC and SISH, and FISH and SISH were 95.1%, 95.7%, and 97.8%, respectively. Conclusions : SISH can be an alternative test for evaluating HER2 amplification because the 97.8% concordance with FISH satisfies the ASCO/ CAP requirement of > 95% concordance with an alternative validated method.
참고문헌 (15)
- Slamon DJ, "Human breast cancer:correlation of relapse and survival with amplification of the HER-2", neu oncogene, 1987, pp.235, 177~182
- Harris L, "American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer", J Clin Oncol, 25, pp.5287~5312 (2007)
- [URL]
- Wolff AC, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, 2007, pp.25, 118~145
- Francis GD, "Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays:correlation between chromogenic(CISH)and automated silver-enhanced(SISH)methods with patient outcome", Diagn Mol Pathol, 18, pp.88~95 (2009)
- Dietel M, "Comparison of automated silver enhanced in situ hybridisation(SISH)and fluorescence ISH(FISH)for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists", Virchows Arch, 451, pp.19~25 (2007)
- Jacobs TW, "Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2", neu in breast cancer, 1999, pp.17, 1974~1982
- Pauletti G, "Assessment of methods for tissue-based detection of the HER-2", neu alteration in human breast cancer:a direct comparison of fluorescence in situ hybridization and immunohistochemistry, 2000, pp.18, 3651~3664
- Owens MA, "HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues", Clin Breast Cancer, 5, pp.63~69 (2004)
- Yaziji H, "HER-2 testing in breast cancer using parallel tissue-based methods", JAMA, 291, pp.1972~1977 (2004)
- Sauter G, "Guidelines for human epidermal growth factor receptor 2 testing:biologic and methodologic considerations", J Clin Oncol, 27, pp.1323~1333 (2009)
- Bartlett JM, "Evaluating HER2 amplification and overexpression in breast cancer", J Pathol, 195, pp.422~428 (2001)
- Carbone A, "Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists", J Mol Diagn, 10, pp.527~536 (2008)
- 김지연, "유방암종에서의 HER-2", neu 유전자 검색을 위한 발색제자리부합화에 관한 연구, 2004, pp.66(06), 447~453[DOI]
- Troxell ML, "Evaluation of Her-2", neu status in carcinomas with amplified chromosome 17 centromere locus, 2006, pp.126, 709~716